

Some studies of the action of betahistine at H1 and H2 receptors for histamine

P.R. GATER, S.E. WEBBER, G.P.H. GUI, C.C. JORDAN¹, N.A. HAYES, J.J. ASHFORD² and J.C. FOREMAN³

Department of Pharmacology, University College London, Gower Street, London WC1E 6BT

¹ Department of Neuropharmacology, Glaxo Group Research Limited, Ware, Hertfordshire, SG12 0DJ

² Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD

Abstract

Betahistine produced a concentration-dependent contraction of the guinea-pig ileum and was about 27 times less active than histamine in this respect. Betahistine induced desensitization of contractile responses to histamine in the guinea-pig ileum. The H1 histamine receptor antagonist mepyramine was a competitive antagonist of the action of betahistine on the guinea-pig ileum.

Betahistine caused relaxation of the rat uterus contracted by acetylcholine, and this action of betahistine was blocked by the H2 receptor antagonist cimetidine. Betahistine had a concentration-dependent positive chronotropic action on isolated guinea-pig atria, and in this respect was tenfold less potent than histamine. The action of betahistine on the atria was blocked by the H2 receptor antagonist YM11170. Betahistine caused a concentration-related contraction of the isolated lung parenchymal strip of the guinea-pig, and YM11170 potentiated this effect.

Betahistine failed to release histamine from rat peritoneal mast cells at concentrations up to 100 μ M and it did not prevent histamine release induced by either substance P or anti-IgE.

Betahistine produced a dose-related flare and wheal reaction when injected intradermally into human skin.

It is concluded that betahistine has agonist activity at both H1 and H2 receptors for histamine.

Introduction

There is evidence that betahistine (2-[2'-methyl amino ethyl pyridine]) is of value in the treatment of Meniere's disease [1]. Meniere's disease is a triad of symptoms including vertigo, deafness and tinnitus which presents with recurrent attacks. It has been suggested that a pathological basis of Meniere's disease is sclerosis of capillary networks in the stria vascularis. The rationale for treating this condition with betahistine is the production of vasodilatation and increased circulation in the stria vascularis. MARTINEZ [2] has studied the effect of betahistine on the circulation of the inner ear and reported

that it increases blood flow. Similar findings have been made by SUGA & SNOW [3]. In another study [4], betahistine was found to increase blood flow in the basilar artery of dogs, and it has largely been assumed that the vasodilator action of betahistine is mediated through histamine receptors in the smooth muscle of the vascular wall. However, most studies with betahistine have preceded the discovery of H2 receptor antagonists and so it is not clear whether its vasodilator action may be mediated through H1 or H2 receptors. Histamine itself causes vasodilatation in the external and internal carotid vasculature of monkeys [5] and, in man, it has been shown that temporal arteries are dilated by an H2 receptor-mediated action of histamine [6]. The evidence cited above that betahistine causes vasodilatation in cerebral vasculature raises the question as to whether this is an H2 receptor action.

Curwain, Holton & Spencer [7] have shown that betahistine stimulates gastric acid secretion in dogs. Histamine stimulation of acid secretion is an H2 histamine receptor effect, and so we have studied the action of betahistine in a number of experimental models to determine the extent of its action at H2 histamine receptors.

Methods

Rat Uterus

Virgin Sprague Dawley rats weighing 125–190 g were primed approximately 12 hours prior to the experiment by injection of stilboestrol 0.1 mg/kg s.c. At the time of the experiment the rat was killed by stunning and section of the carotid arteries. The abdominal cavity was opened by a midline incision and the two horns of the uterus were dissected free. One horn was suspended in a 5 ml organ bath and maintained at 35°C in DeJalon solution gassed with 95% oxygen, 5% carbon dioxide. The preparation was allowed to rest for approximately 20 minutes before the commencement of the experiment. Contractions of the uterus were recorded isotonicly by a photo-electric transducer connected to a

³ To whom correspondence should be addressed.

Servoscribe pen recorder. A tension of 0.5 g wt was applied to the tissue. The cycle time for the application of agonists to the uterus consisted of 45 sec of contact with the agonist, followed by 2 washes with DeJalon solution taking 2.5 min and then a rest of 2 min before the next addition of agonist.

Guinea-pig ileum

Male Hartley guinea-pigs weighing 300–500 g were killed by stunning and exsanguination. The abdominal cavity was opened by a midline incision and the terminal ileum dissected out and washed through with Tyrode solution. A section of approximately 1–2 cm was mounted in an organ bath containing Tyrode solution at 37°C, gassed with oxygen 95%, carbon dioxide 5%. The tissue was allowed to rest for approximately 1 hour with repeated washing in Tyrode solution before the experimental protocol was commenced. The tension placed on the tissue was 0.5 g wt. Contractions of the ileum were recorded isotonicly using a photo-electric transducer connected to a potentiometric chart recorder.

Guinea-pig atria

Male Hartley guinea-pigs weighing 200–300 g were killed by stunning and exsanguination. The thoracic cavity was opened and the heart and lungs were dissected free. An isolated atrial preparation was prepared as previously described [8]. The tissue was bathed in McEwan solution gassed with 95% oxygen, 5% carbon dioxide. Contractions were recorded isometrically, and the average atrial rate was recorded on a ratemeter.

Histamine release

The effects of betahistine on histamine release were determined using a preparation of rat peritoneal mast cells prepared as described previously [9]. Sprague Dawley rats weighing between 150 and 250 g were used for these experiments. The rats were killed by cervical dislocation following anaesthesia with nitrous oxide, and the peritoneal cavity washed out with 5 mls of heparinised saline (heparin 25 U/ml; NaCl 154 mM) through a midline incision in order to obtain peritoneal cells for the experiment. Histamine release from the cells in response to various agents including betahistine were expressed as a percentage of the total histamine content of the cells. For these experiments, peritoneal cells were incubated in HEPES-Tyrode solution.

Human skin

Betahistine was compared with histamine for its ability to produce wheal and flare reactions in human skin by the method described previously [10]. Histamine or betahistine was injected intradermally into the volar surface of the human forearm of healthy adult volunteers. The volume of injection was 25 μ l and the flare response was measured 3 min after injection and the wheal response 12 min after injection: these being the times at which the respective responses reached maximum. Volunteers for this experiment were taking no medication at the time of, or in the two weeks prior to, the experiments.

Guinea-pig parenchymal lung strip

Male Hartley guinea-pigs weighing 200–300 g were killed by stunning and exsanguination. The thoracic cavity was opened by a midline incision and the heart and lungs dissected free and placed in Tyrode solution. Strips of parenchymal tissue were cut from the periphery of the lungs. The

size of the strips was approximately 1–1.5 cm in length and 3–4 mm in width. The strips were mounted in a 2 ml organ bath containing Tyrode solution maintained at 37°C and gassed with oxygen 95% and carbon dioxide 5%. Contractions of the tissue were recorded isotonicly using a photo-electric transducer. The tension placed on the tissue was approximately 0.5 g.wt. The tissue was allowed to rest for approximately 1 hour before the experimental protocol commenced and during this time the bathing fluid was changed every 10 min.

Materials

The sources of materials used in this study were as follows:

Cimetidine – Smith, Kline & French Research Ltd, U.K.; 3-[[[2-(diaminomethylene)-amino]-4-thiazolyl] methyl]thio]-N2-sulfamoyl-propionamide (YM11170)-Hoechst (UK) Ltd; Betahistine – Duphar Laboratories Ltd, U.K.; substance P – Peninsula Laboratories Europe; goat anti (rat IgE) – Miles Laboratories Ltd, U.K.; histamine acid phosphate and acetylcholine iodide, B.D.H. England; mepyramine – May & Baker Ltd, U.K.; stilboestrol – WB Pharmaceuticals, U.K.

All other chemicals and reagents were of 'Analar' or equivalent quality.

Results

Rat uterus

Neither histamine nor betahistine at concentrations up to 10 μ M produced any contraction of this preparation. To examine the possible smooth muscle relaxing effect of histamine and betahistine the uterus was contracted with acetylcholine. Concentration-dependent contraction of the uterus to acetylcholine was obtained in the concentration range 0.5–5 μ M. Figure 1 shows that histamine produced a dose-dependent inhibition of the contraction of the rat uterus induced by acetylcholine, 2 μ M, and Figure 2 shows the effect of histamine and betahistine at fixed concentrations of 1 and 10 μ M respectively on the acetylcholine dose-response curve on the uterus. Both histamine and betahistine produced small but significant rightward shifts of the acetylcholine dose-response curve on the rat uterus. The antagonism by betahistine of the contraction of the uterus induced by acetylcholine could be reversed by the H2 histamine receptor antagonist cimetidine (Figure 3).

Guinea-pig ileum

Both histamine and betahistine produced concentration-dependent contractions of the guinea-pig ileum (Figure 4). The EC₅₀ for histamine was found to 0.1 μ M and that for betahistine 2.7 μ M. Histamine is, therefore, 27 times more potent than betahistine in producing 50% of the maximum contraction of the guinea-pig ileum.




Figure 1

Concentration-response curve for histamine-induced relaxation of the isolated rat uterus. The uterus was caused to contract with acetylcholine, 2 μM , and histamine, at the concentrations indicated, was added to produce relaxation of the acetylcholine-induced contraction. The relaxation induced by each concentration of histamine has been expressed as a percentage of the maximum relaxation of the contracted uterus that could be obtained with histamine. Data is from a single experiment.

The H1 histamine receptor antagonist mepyramine produced a concentration-dependent rightward shift of the betahistamine dose-response curve on the guinea-pig ileum (data not shown). The pA_2 value for mepyramine calculated from a Schild plot of this data was found to be 10.1.

It has been established for many years that histamine produces desensitization of guinea-pig

ileum [11] and this has been used as a criterion for the identification of histamine in tissue fluids. Desensitization of the smooth muscle of the guinea-pig ileum to histamine also resulted in desensitization of the tissue towards betahistamine. The procedure for studying desensitization of the guinea-pig ileum has previously been described [12] but briefly, recovery of the response to an agonist following exposure to high concentrations of desensitizing agent was monitored by measuring the responses to the agonist at various time intervals. Post-desensitization dose-ratios were calculated from log dose-response curves established at the beginning of the experiment. The fraction of receptors remaining in the desensitized state (Pd) was calculated from the model proposed by RANG and RITTER [13]. The high concentration of agonist used for desensitization has been expressed as multiples of its EC_{50} value. Figure 5a shows that histamine desensitized the tissue: the recovery of the response to histamine after desensitization being faster for the lower desensitizing dose. Similarly a high dose of betahistamine resulted in desensitization towards itself (Figure 5b). Figure 5c shows that a high dose of histamine desensitized the tissue to the action of betahistamine: the rate of recovery of the response to betahistamine being inversely proportional to the initial desensitizing dose of histamine. Figure 5d likewise shows that a high dose of betahistamine desensitized the tissue to the action of histamine.

Guinea-pig atria

Both histamine and betahistamine produced a concentration-dependent positive chronotropic




Figure 2

Concentration-response curves for acetylcholine on the isolated rat uterus. The response to acetylcholine is expressed as a percentage of the maximum contraction produced by this agent. ●—● acetylcholine alone; ▲—▲ acetylcholine in the presence of betahistamine 10 μM ; ■—■ acetylcholine in the presence of histamine 1 μM . Points represent means \pm s.e.m. from 3 experiments.




Figure 3. Concentration-response curves for acetylcholine on the isolated rat uterus. The response to acetylcholine is expressed as a percentage of the maximum response to that agent. \blacktriangle — \blacktriangle acetylcholine alone; \blacksquare — \blacksquare acetylcholine in the presence of betahistine $1 \mu\text{M}$; \bullet --- \bullet acetylcholine in the presence of betahistine, $1 \mu\text{M}$ and cimetidine, $100 \mu\text{M}$. Points represent means \pm s.e.m. from 3 experiments.

effects on the guinea-pig atrial preparation in the concentration ranges 0.5 to 10 and 0.5 to $100 \mu\text{M}$ respectively. The dose of histamine required to increase the atrial rate by 40% was $1 \mu\text{M}$ whereas the dose of betahistine required to produce the

same effect was $10 \mu\text{M}$. Histamine is, therefore, about tenfold more potent than betahistine on the preparation. The positive chronotropic effect of betahistine on this preparation was inhibited by the specific H_2 histamine receptor antagonist YM11170 [14] (Figure 6).

Guinea-Pig lung strip

Betahistine produced concentration-dependent contractions of the guinea-pig parenchymal lung strip preparation in the concentration range $1 \mu\text{M}$ to $400 \mu\text{M}$ (Figure 7) with an EC_{50} of $30 \mu\text{M}$. The histamine H_2 receptor antagonist, YM11170, produced a two-fold shift to the left of the betahistine concentration-response curve (Figure 7). The EC_{50} for betahistine in the presence of YM11170 was $14 \mu\text{M}$. Thus, blocking of H_2 histamine receptors potentiates the effect of betahistine in producing contraction of the guinea-pig parenchymal lung strip preparation.

Histamine release from rat peritoneal mast cells

Table 1 shows that substance P and anti-IgE caused a release of histamine from rat peritoneal mast cells. However, at concentrations up to $100 \mu\text{M}$ betahistine failed to induce histamine release from rat mast cells. Table 1 also shows that betahistine in concentrations up to $10 \mu\text{M}$ did not inhibit the histamine release induced by substance P. In similar experiments, betahistine at concentrations up to $10 \mu\text{M}$ failed to inhibit histamine release induced by anti-IgE.




Figure 4 Concentration-response curves for histamine (\circ) and betahistine (\bullet) producing contraction of the isolated guinea-pig ileum. Responses have been expressed as a percentage of the maximum contractile response to histamine. Points are the means \pm s.e.m. from 9 experiments.




Figure 5

Desensitization of receptors in the isolated guinea-pig ileum to histamine and betahistine. Recovery after a desensitizing dose of histamine or betahistine is expressed as a rate of change in the number of receptors remaining in the desensitized state (Pd). Explanation of the calculation of Pd is given in the text. (a) the recovery of the response to histamine following desensitization to histamine (b) the recovery of the response to betahistine following desensitization to betahistine (c) the recovery of the response to betahistine following desensitization to histamine (d) the recovery of the response to histamine following desensitization to betahistine. Different symbols show experiments with different doses of desensitizing agent and the dose of desensitizing agent is given as a multiple of the EC_{50} value for the agent on the preparation. The multiples of EC_{50} were: (a) 153-●; 39-○. (b) 37-●. (c) 1430-○; 2900-●; 153-▲; 45-■. (d) 300-●; 56-○; 25-▲. Each line represents data from a single experiment.




Figure 6

Concentration-response curves for the increase in control beating rate of isolated guinea-pig atria induced by betahistine (○) and betahistine in the presence of YM11170, 0.1 µM (●). Changes in control beating rate induced by the drugs have been expressed as percentage increases over the control beating rate in the absence of drug which had a value of 258 ± 4.5 (means \pm s.e.m. $n = 31$) beats/min. Each point is the mean of 3 experiments.




Figure 7

Concentration-response curves for betahistine-induced contraction of the isolated parenchymal lung strip of the guinea-pig. Responses are expressed as percentage of the maximum response to betahistine alone. ●—● betahistine alone; ○—○ betahistine in the presence of the H₂ histamine receptor antagonist YM11170, 1 µM. Data are the means (\pm s.e.m.) of 5 experiments.

Human skin responses

Both histamine, 0.075 to 0.75 n-moles, and betahistine, 2.5 to 25 n-moles, produced dose-dependent flare and wheal reactions in human skin when injected intradermally (Table 2). For the production of a flare of 1400 mm² and a wheal of 45 mm² betahistine was sixty five times less potent than histamine.

Discussion

Betahistine is of value in the treatment of Meniere's disease but the symptomatic relief produced by the drug in this condition has an unknown mechanism. There is some evidence that Meniere's disease is associated with reduced blood flow in parts of the inner ear and it is, therefore, reasonable to speculate that vasodilator actions of betahistine and the resulting improved circulation in the inner ear are responsible for the improvement seen during treatment with betahistine. In man, histamine produces vasodilatation particularly on the arterial side of the circulation and this effect appears to be mediated in many vessels by both H₁ and H₂ histamine receptors. In fact, there is evidence from primates that external carotid vessels are dilated through an H₂ receptor mechanism [5] while internal carotid arteries are dilated by H₁ and H₂ receptor mechanisms [5]. In man, histamine-mediated dilatation of temporal

Table 1

Histamine release induced by betahistine from rat peritoneal mast cells, and the effect of betahistine on histamine release induced by substance P. Data are means of 3 experiments \pm s.e.m.

Drug and Concentration (μ M)	Histamine release (% of total)
Betahistine	
1	0.9 \pm 0.4
10	0.1 \pm 0
100	0
Substance P	
10	31.4 \pm 4.6
Ant - 1gE	
1 in 200 dilution	40.7 \pm 0.4
Substance P	
5 alone	39.2 \pm 6.0
5 + betahistine 0.1	34.7 \pm 8.6
5 + betahistine 1	39.0 \pm 6.3
5 + betahistine 10	40.6 \pm 7.5

Table 2

Betahistine-induced flare and wheal responses in human skin. Each value is the mean of two separate experiments. The areas of flare and wheal responses to a saline control have been subtracted from the responses to histamine and betahistine to yield the value in the table.

Drug and amount injected (n-moles)	Area of flare (mm ²)	Area of wheal (mm ²)
Histamine	0.075	1283
	0.25	1780
	0.75	1873
Betahistine	2.5	1152
	7.5	1442
	25.0	960

arteries is brought about through the activation of H₂ receptors [6]. The results presented in this paper indicate that betahistine exerts H₂ as well as H₁ actions and hence both of these effects need to be taken into account when considering its mechanism of action in Meniere's disease.

We have shown that betahistine produces contraction of the smooth muscle of the guinea-pig ileum and that this effect is mediated through an H₁ receptor since it is antagonised by the selective H₁ antagonist mepyramine and the pA₂ value for mepyramine at this receptor was found to be about 10 which is similar to pA₂ values reported for mepyramine in other tissues [15]. The cross-desensitization between histamine and betahistine in this preparation is evidence that the two drugs are acting through a similar mechanism. The contraction of the guinea-pig lung strip induced by betahistine is also evidence of an H₁ action of this compound since it is established that H₁ histamine agonists contract the guinea-pig lung strip whereas H₂ receptor agonists prod-

uce relaxation [16, 17]. Evidence that betahistine affects both H₂ as well as H₁ receptors in the guinea-pig lung was obtained by showing that the selective H₂ antagonist, YM11170 produced a shift to the left of the concentration-response curve for betahistine on the guinea-pig lung strip preparation. Blocking H₂ receptors with YM11170 would be expected to prevent H₂ receptor-mediated relaxation of the lung strip by removing physiological antagonism of the H₁ contractile effect of betahistine. Hence, removal of the H₂ receptor-mediated smooth muscle relaxant effect results in an increased response of the lung strip to betahistine.

The rat uterus is one of the classical preparations for examining H₂ histamine receptors. The data presented in this paper show that histamine and betahistine produce relaxation of rat uterus precontracted with acetylcholine, this relaxation being manifest as a rightward shift of the acetylcholine concentration-response curve in the presence of either betahistine or histamine.

Relaxation of the rat uterus by betahistine is reversed by the specific H₂ receptor antagonist cimetidine, indicating that the relaxant effect of betahistine on the rat uterus is mediated by an H₂ receptor.

Isolated guinea-pig atria provide another preparation for examining the effects of H₂ histamine receptor agonists, and betahistine has been shown to have a positive chronotropic action on the atrial preparation which was blocked by the potent, selective H₂ receptor antagonist, YM11170. Hence this is further evidence for H₂ receptor agonist activity of betahistine.

Another well-characterized preparation in which H₂ receptors mediate an effect is gastric secretion from the stomach. There are conflicting reports about the activity of betahistine on gastric acid secretion. CURWAIN et al. [7] demonstrated that betahistine increased both gastric mucosal blood flow and gastric acid secretion from the Heidenhein pouch of the dog. In contrast, COCHRAN et al. [18] failed to demonstrate an increase in gastric acid secretion induced by betahistine in man. In the experiments of COCHRAN et al. [18] the concentration of betahistine was high and produced headache and flushing in five of the six subjects and hence it is possible that the H₁ side-effects limited the dose that could be given in these experiments. If betahistine has less potency at H₂ receptors than histamine, the dose reached in these studies was probably insufficient to activate the H₂ receptors mediating gastric acid secretion.

In a previous study [19] betahistine was shown to release histamine from isolated guinea-pig atria. However, we were unable to induce histamine release from rat peritoneal mast cells with betahistine at concentrations up to 100 μ M. In the studies of LIGHT and HUGHES [19] the concentrations of betahistine which induced histamine release from the guinea-pig tissue were between 360 μ M and 1.47 mM which are very high concentrations and a cytotoxic effect of the drug cannot be ruled out. In fact, in the same study, compound 48/80 released histamine but again at concentrations which would normally be considered to be cytotoxic. It should be pointed out, however, that mast cells from different species and different sources within a species show heterogeneous responses to histamine releasing agents [20]. We used rat peritoneal mast cells in this study because they have been shown to be a good model for the actions of histamine releasing

agents in human skin [10].

We have also demonstrated that betahistine produces a wheal and flare reaction in human skin. This probably represents an H₁ receptor action since it has previously been shown that the wheal-and-flare inducing effect of histamine in human skin is inhibited by H₁ receptor antagonists but not by H₂ receptor antagonists [10]. Furthermore, it probably represents a direct effect of betahistine rather than an indirect action through histamine release since we were unable to demonstrate histamine release *in vitro* in response to betahistine (Table 1).

A recent study by ARRANG et al. [21] has shown that betahistine displaces [³H]-mepyramine binding to H₁ receptors in guinea-pig brain. Thus, there is evidence from the data presented in this paper and a variety of other studies that betahistine exerts agonist actions at H₁ receptors. We have now presented evidence to show that betahistine also exerts agonist action at H₂ histamine receptors. From the studies on guinea-pig atria, betahistine appears to be about ten times less potent than histamine at H₂ receptors whereas data from human skin and guinea-pig ileum indicate that betahistine is about 30 to 60 times less potent than histamine at H₁ receptors. It seems, therefore, that whilst betahistine has significant H₁ effects, it is more potent at H₂ receptors. The combined H₁ and H₂ agonist actions of betahistine may be of importance in its therapeutic effect in Meniere's syndrome, although to test this hypothesis it would be necessary to study the action of H₁ and H₂ antagonists on the response to betahistine of human cochlear blood vessels. There is evidence in experimental animals that betahistine increases cochlear and basilar blood flow but apparently no analysis of the H₁ and H₂ components of this [2-4].

Received 5 October 1985; accepted 10 December 1985

References

- [1] I.J.C. FREW and G.N. MENON, *Betahistine hydrochloride in Meniere's disease*, Postgrad Med. J. 52, 501-503 (1976).
- [2] D.M. MARTINEZ, *The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals*, Acta Otolaryngol. Suppl. 305, 29-47 (1971).
- [3] F. SUGA and J.B. SNOW, *Cochlear blood flow in response to vasodilating drugs and some related agents*, Laryngoscope 79, 1956-1979 (1969).
- [4] W.D. ANDERSON and N.G. KUBICEK, *Effects of betahistine HCL, nicotinic acid and histamine on basilar blood*

- flow in anaesthetized dogs*, *Stroke* 2, 409–415 (1971).
- [5] J.W. DUCKWORTH, J.W. LANCE, G.D.A. LORD and E.J. MYLECHARANE, *Histamine receptors in the cranial circulation of the monkey*, *Br. J. Pharmacol.* 58, 444P (1976).
- [6] W.E. GLOVER, P.R. CARROLL and N. LATT, *Histamine receptors in human temporal and rabbit ear arteries*, In Proceedings of the International Symposium on Histamine H₂-receptor antagonists (Ed. C.J. WOODS and M.A. SIMKINS) Smith Kline & French Labs Ltd, Welwyn Garden City, 169–174 (1973).
- [7] B.P. CURWAIN, P. HOLTON and J. SPENCER, *The effect of betahistine on gastric secretion and mucosal blood flow in conscious dogs*, *Br. J. Pharmacol.* 46, 351–354 (1972).
- [8] Department of Pharmacology, University of Edinburgh, *Pharmacological Experiments on Isolated Preparations*, E. & S. Livingstone Ltd, Edinburgh & London (1968).
- [9] J.C. FOREMAN and J.L. MONGAR, *The role of the alkaline earth ions in anaphylactic histamine secretion*, *J. Physiol.* 224, 753–769 (1972).
- [10] J.C. FOREMAN, C.C. JORDAN, P. OEHME and H. RENNER, *Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin*, *J. Physiol.* 335, 449–465 (1983).
- [11] G.S. BARSOU and J.H. GADDUM, *The Pharmacological estimation of adenosine and histamine in blood*, *J. Physiol.* 85, 1–14 (1935).
- [12] C.C. JORDAN, *An examination of desensitization as a basis for defining substance P-like agonist activity*, In *Neuropeptides and Neural Transmission*, A.C. MARSAN and W.Z. TRACZYK (Eds) Raven Press, New York, 131–140 (1980).
- [13] H.P. RANG and J.M. RITTER, *On the mechanism of desensitization at cholinergic receptors*, *Molec. Pharmacol.* 6, 357–382 (1970).
- [14] M. TAKEDA, T. TAGAKI, Y. YASHIMA and H. MAENO, *Effect of a new potent H₂-blocker 3-[[[2-(diaminomethylene)-amino]-4-thiazolyl]methyl]thio]-N₂-sulfamoyl-propionamide (YM11170) on gastric secretion, ulcer formation and weight of male accessory sex organs in rats*, *Arzneimittel Forschung* 32, 784–737 (1982).
- [15] A.S.F. ASH and H.O. SCHILD, *Receptors mediating some actions of histamine*, *Br. J. Pharmacol.* 27, 427–439 (1966).
- [16] J.M. DRAZEN and M.W. SCHNEIDER, *Comparative responses of tracheal spirals and parenchymal strips to histamine and carbachol in vitro*, *J. Clin. Invest.* 61, 1441–1447 (1978).
- [17] J.C. FOREMAN, T.J. RISING and S.E. WEBBER, *A study of the histamine H₂-receptor mediating relaxation of the parenchymal lung strip preparation of the guinea-pig*, *Br. J. Pharmacol.* 86, 465–473 (1985).
- [18] K.M. COCHRAN, J.G. ALLAN and R.I. RUSSELL, *A study of the effect of betahistine on gastric acid secretion in man*, *Curr. Med. Res. Opinion* 2, 63–66 (1974).
- [19] K.E. LIGHT and M.J. HUGHES, *Liberation of histamine by compound 48/80, tolazoline, betahistine and burimamide from isolated, spontaneously beating guinea pig and rabbit atrial pairs*, *Agents and Actions* 9, 141–147 (1979).
- [20] F.L. PEARCE, *Mast cell heterogeneity*, *Trends in Pharmacol. Sci.* 4, 165–167 (1983).
- [21] J.M. ARRANG, M. GARBARG, TAM THANH QUACH, MY DAM TRUNG TUONG, E. YERAMIAN and J.-C. SCHWARTZ, *Actions of betahistine at histamine receptors in the brain*, *Eur. J. Pharmacol.* 111, 73–84 (1985).